Biomarkers.

Background: Amyloid status is a core marker of Alzheimer's disease and can be defined qualitatively through expert neuroradiologist visual read and quantitively through SUVR analysis. We investigate differences in amyloid status classification between racial groups.

Method: We analysed data from 944 participants enrolled in the Global Alzheimer's Platform (GAP) Bio-Hermes trial.

An exploratory qualitative study of inter-agency health and social service partnerships focused on Aboriginal and Torres Strait Islander clients.

Background: The siloed nature of the health and social service system threatens access for clients engaging numerous organisations. Many Aboriginal and Torres Strait Islander people face adverse circumstances which contribute to multiple health and social needs. Effective relationships between health and social services are integral to coordinated service provision to meet the diverse needs of Aboriginal and Torres Strait Islander clients.

A Functional Basis for the Assembly of Australian Subtropical Rainforest Tree Communities.

Understanding the role of climate in the assembly of rainforest tree communities is informative for predicting how future climates will impact species and communities. We surveyed rainforest tree communities across the Australian subtropics (spanning 600 to 2500 mm rainfall year) and measured functional traits on 285 (91%) of all recorded species. We used principal component analysis to create axes approximating species' hydraulic strategies, leaf economics and stature and included these as predictors in joint species distribution models, along with traits describing dispersal ability and leaf phenology.

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence.

Decades of research have provided evidence that Alzheimer's disease (AD) is caused in part by cerebral accumulation of amyloid beta-protein (Aβ). In 2023, the US Food and Drug Administration gave full regulatory approval to a disease-modifying Aβ antibody for early AD. Secondary prevention trials with Aβ antibodies are underway.